Orgenesis Inc. 8-K

What Happened Orgenesis Inc. held a special meeting on May 27, 2026 and shareholders approved an amendment to its Articles of Incorporation to increase authorized common shares from 14,583,333 to 150,000,000. The Company filed the Certificate of Amendment with the Nevada Secretary of State on June 2, 2026, effective immediately. At the same meeting shareholders also approved a previously disclosed Convertible Loan Agreement (dated September 10, 2025) that could result in issuance of common stock, and they ratified Kesselman & Kesselman C.P.A.s (a PwC member firm) as the Company’s independent auditors for fiscal 2025.

Key Details

• Authorized shares increased from 14,583,333 to 150,000,000 (filed June 2, 2026).
• Special Meeting held May 27, 2026; 6,415,731 shares represented (~65.27% of outstanding) — quorum present.
• Proposal 1 (increase authorized shares) vote: For 5,153,345; Against 61,005; Abstain 1,201,381.
• Proposal 2 (approve Convertible Loan Agreement / potential share issuance) vote: For 5,172,526; Against 27,026; Abstain 1,201,280. Agreement parties include Theracell Laboratories IKE and Alpha Prosperity Fund SPC (Segregated Portfolio P).
• Proposal 3 (ratify auditors) vote: For 6,400,038; Against 14,552; Abstain 1,141.
• The Certificate of Amendment is attached as Exhibit 3.1 to the Form 8-K filed June 2, 2026.

Why It Matters Raising the number of authorized shares gives Orgenesis the legal ability to issue many more shares in the future for financing, conversions or other corporate purposes; such issuances, if made, would dilute current shareholders. Approval of the Convertible Loan Agreement confirms the company can issue shares under that financing arrangement if and when conversion terms are met. Ratification of auditors maintains continuity of the company’s financial oversight. These are governance and capital-structure actions investors should note when assessing potential dilution and future funding plans.